Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 353

1.

Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial.

Pavord ID, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, Harrison T, Houghton C, Oldfield K, Papi A, Williams M, Weatherall M, Beasley R; Novel START Study Team.

Lancet Respir Med. 2020 Mar 11. pii: S2213-2600(20)30053-9. doi: 10.1016/S2213-2600(20)30053-9. [Epub ahead of print]

PMID:
32171064
2.

Efficacy and Safety of treatment with dupilumab for severe asthma.

Agache I, Song Y, Rocha C, Beltran J, Posso M, Steiner C, Alonso-Coello P, Akdis C, Akdis M, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Mäkelä M, Martín IH, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Quirce S, Sastre J, Shamji M, Schwarze J, Canelo-Aybar C, Palomares O, Jutel M.

Allergy. 2020 Mar 10. doi: 10.1111/all.14268. [Epub ahead of print]

PMID:
32154939
3.

Eosinophil-derived neurotoxin and clinical outcomes with mepolizumab in severe eosinophilic asthma.

Howarth P, Quirce S, Papi A, Israel E, Mallett S, Bates S, Yancey S, Albers FC, Kwon N.

Allergy. 2020 Mar 9. doi: 10.1111/all.14266. [Epub ahead of print] No abstract available.

PMID:
32147844
4.

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma.

Agache I, Rocha C, Beltran J, Song Y, Posso M, Solà I, Alonso-Coello P, Akdis C, Akdis M, Canonica W, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Mäkelä M, Martín IH, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Quirce S, Sastre J, Shamji M, Schwarze J, Canelo-Aybar C, Palomares O, Jutel M.

Allergy. 2020 Feb 16. doi: 10.1111/all.14235. [Epub ahead of print]

PMID:
32064642
5.

Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma.

Agache I, Beltran J, Akdis C, Akdis M, Canelo-Aybar C, Canonica GW, Casale T, Chivato T, Corren J, Del Giacco S, Eiwegger T, Firinu D, Gern JE, Hamelmann E, Hanania N, Mäkelä M, Martín IH, Nair P, O'Mahony L, Papadopoulos NG, Papi A, Park HS, Pérez de Llano L, Posso M, Rocha C, Quirce S, Sastre J, Shamji M, Song Y, Steiner C, Schwarze J, Alonso-Coello P, Palomares O, Jutel M.

Allergy. 2020 Feb 8. doi: 10.1111/all.14221. [Epub ahead of print]

PMID:
32034960
6.

SABINA: An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries.

Janson C, Menzies-Gow A, Nan C, Nuevo J, Papi A, Quint JK, Quirce S, Vogelmeier CF.

Adv Ther. 2020 Mar;37(3):1124-1135. doi: 10.1007/s12325-020-01233-0. Epub 2020 Jan 24.

7.

ICS-formoterol reliever therapy stepwise treatment algorithm for adult asthma.

Beasley R, Braithwaite I, Semprini A, Kearns C, Weatherall M, Harrison TW, Papi A, Pavord ID.

Eur Respir J. 2020 Jan 9;55(1). pii: 1901407. doi: 10.1183/13993003.01407-2019. Print 2020 Jan. No abstract available.

PMID:
31919194
8.

Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis.

Hartley BF, Barnes NC, Lettis S, Compton CH, Papi A, Jones P.

Respir Res. 2020 Jan 6;21(1):5. doi: 10.1186/s12931-019-1262-0.

9.

Dose-response relationship of ICS/fast-onset LABA as reliever therapy in asthma.

Beasley R, Harper J, Bird G, Dunphy H, Semprini A, Pavord ID, Papi A, Weatherall M.

BMC Pulm Med. 2019 Dec 28;19(1):264. doi: 10.1186/s12890-019-1014-4.

10.

A multinational observational study identifying primary care patients at risk of overestimation of asthma control.

Kritikos V, Price D, Papi A, Infantino A, Ställberg B, Ryan D, Lavorini F, Chrystyn H, Haughney J, Lisspers K, Gruffydd-Jones K, Román Rodríguez M, Høegh Henrichsen S, van der Molen T, Carter V, Bosnic-Anticevich S.

NPJ Prim Care Respir Med. 2019 Dec 5;29(1):43. doi: 10.1038/s41533-019-0156-4.

11.

Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.

Virchow JC, Kuna P, Paggiaro P, Papi A, Singh D, Corre S, Zuccaro F, Vele A, Kots M, Georges G, Petruzzelli S, Canonica GW.

Lancet. 2019 Nov 9;394(10210):1737-1749. doi: 10.1016/S0140-6736(19)32215-9. Epub 2019 Sep 30.

PMID:
31582314
12.

Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies.

Criner GJ, Celli BR, Singh D, Agusti A, Papi A, Jison M, Makulova N, Shih VH, Brooks L, Barker P, Martin UJ, Newbold P.

Lancet Respir Med. 2020 Feb;8(2):158-170. doi: 10.1016/S2213-2600(19)30338-8. Epub 2019 Sep 28.

PMID:
31575508
13.

Comparative effectiveness of triple therapy versus dual bronchodilation in COPD.

Voorham J, Corradi M, Papi A, Vogelmeier CF, Singh D, Fabbri LM, Kerkhof M, Kocks JH, Carter V, Price D.

ERJ Open Res. 2019 Aug 30;5(3). pii: 00106-2019. doi: 10.1183/23120541.00106-2019. eCollection 2019 Jul.

14.

ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions.

Bourdin A, Bjermer L, Brightling C, Brusselle GG, Chanez P, Chung KF, Custovic A, Diamant Z, Diver S, Djukanovic R, Hamerlijnck D, Horváth I, Johnston SL, Kanniess F, Papadopoulos N, Papi A, Russell RJ, Ryan D, Samitas K, Tonia T, Zervas E, Gaga M.

Eur Respir J. 2019 Sep 28;54(3). pii: 1900900. doi: 10.1183/13993003.00900-2019. Print 2019 Sep.

PMID:
31467120
15.

Circulating neutrophils levels are a predictor of pneumonia risk in chronic obstructive pulmonary disease.

Pascoe SJ, Papi A, Midwinter D, Lettis S, Barnes N.

Respir Res. 2019 Aug 23;20(1):195. doi: 10.1186/s12931-019-1157-0.

16.

Co-carcinogenic effects of vitamin E in prostate.

Vivarelli F, Canistro D, Cirillo S, Papi A, Spisni E, Vornoli A, Croce CMD, Longo V, Franchi P, Filippi S, Lucarini M, Zanzi C, Rotondo F, Lorenzini A, Marchionni S, Paolini M.

Sci Rep. 2019 Aug 12;9(1):11636. doi: 10.1038/s41598-019-48213-1.

17.

Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA.

Albers FC, Papi A, Taillé C, Bratton DJ, Bradford ES, Yancey SW, Kwon N.

Respir Res. 2019 Jul 30;20(1):169. doi: 10.1186/s12931-019-1134-7.

18.

Right Ventricle Function in Patients with Acute Coronary Syndrome and Concomitant Undiagnosed Chronic Obstructive Pulmonary Disease.

Pavasini R, Fiorencis A, Tonet E, Gaudenzi E, Balla C, Maietti E, Biscaglia S, Papi A, Ferrari R, Contoli M, Campo G.

COPD. 2019 Aug;16(3-4):284-291. doi: 10.1080/15412555.2019.1645105. Epub 2019 Jul 29.

PMID:
31357891
19.

Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial.

Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MK, Hartley B, Lange P, Lettis S, Lipson DA, Lomas DA, Martinez FJ, Papi A, Roche N, van der Valk RJP, Wise R, Singh D.

Lancet Respir Med. 2019 Sep;7(9):745-756. doi: 10.1016/S2213-2600(19)30190-0. Epub 2019 Jul 4.

PMID:
31281061
20.

Airway inflammatory profile is correlated with symptoms in stable COPD: A longitudinal proof-of-concept cohort study.

Contoli M, Baraldo S, Conti V, Gnesini G, Marku B, Casolari P, Scrigner P, Morelli P, Saetta M, Spanevello A, Papi A.

Respirology. 2020 Jan;25(1):80-88. doi: 10.1111/resp.13607. Epub 2019 Jun 28.

21.

IL-22 and its receptors are increased in human and experimental COPD and contribute to pathogenesis.

Starkey MR, Plank MW, Casolari P, Papi A, Pavlidis S, Guo Y, Cameron GJM, Haw TJ, Tam A, Obiedat M, Donovan C, Hansbro NG, Nguyen DH, Nair PM, Kim RY, Horvat JC, Kaiko GE, Durum SK, Wark PA, Sin DD, Caramori G, Adcock IM, Foster PS, Hansbro PM.

Eur Respir J. 2019 Jul 18;54(1). pii: 1800174. doi: 10.1183/13993003.00174-2018. Print 2019 Jul.

PMID:
31196943
22.

Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.

Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, Harrison T, Houghton C, Oldfield K, Papi A, Pavord ID, Williams M, Weatherall M; Novel START Study Team.

N Engl J Med. 2019 May 23;380(21):2020-2030. doi: 10.1056/NEJMoa1901963. Epub 2019 May 19.

PMID:
31112386
23.

Benralizumab for the Prevention of COPD Exacerbations.

Criner GJ, Celli BR, Brightling CE, Agusti A, Papi A, Singh D, Sin DD, Vogelmeier CF, Sciurba FC, Bafadhel M, Backer V, Kato M, Ramírez-Venegas A, Wei YF, Bjermer L, Shih VH, Jison M, O'Quinn S, Makulova N, Newbold P, Goldman M, Martin UJ; GALATHEA Study Investigators; TERRANOVA Study Investigators.

N Engl J Med. 2019 Sep 12;381(11):1023-1034. doi: 10.1056/NEJMoa1905248. Epub 2019 May 20.

PMID:
31112385
24.

Asthma progression and mortality: the role of inhaled corticosteroids.

O'Byrne P, Fabbri LM, Pavord ID, Papi A, Petruzzelli S, Lange P.

Eur Respir J. 2019 Jul 18;54(1). pii: 1900491. doi: 10.1183/13993003.00491-2019. Print 2019 Jul. Review.

25.

Triple therapy for all patients with severe symptomatic COPD at risk of exacerbations.

Papi A, Petruzzelli S, Vezzoli S, Georges G, Fabbri LM.

Eur Respir J. 2019 Apr 18;53(4). pii: 1900147. doi: 10.1183/13993003.00147-2019. Print 2019 Apr. No abstract available.

PMID:
31000665
26.

Epigallocatechin-3-gallate inhibits doxorubicin-induced inflammation on human ovarian tissue.

Fabbri R, Macciocca M, Vicenti R, Caprara G, Piccinni MP, Paradisi R, Terzano P, Papi A, Seracchioli R.

Biosci Rep. 2019 May 14;39(5). pii: BSR20181424. doi: 10.1042/BSR20181424. Print 2019 May 31.

27.

Letter from Italy.

Papi A.

Respirology. 2019 Jun;24(6):605-606. doi: 10.1111/resp.13554. Epub 2019 Apr 8. No abstract available.

28.

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA.

Singh D, Fabbri LM, Vezzoli S, Petruzzelli S, Papi A.

Int J Chron Obstruct Pulmon Dis. 2019 Feb 28;14:531-546. doi: 10.2147/COPD.S196383. eCollection 2019.

29.

Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study.

Postma DS, Brightling C, Baldi S, Van den Berge M, Fabbri LM, Gagnatelli A, Papi A, Van der Molen T, Rabe KF, Siddiqui S, Singh D, Nicolini G, Kraft M; ATLANTIS study group.

Lancet Respir Med. 2019 May;7(5):402-416. doi: 10.1016/S2213-2600(19)30049-9. Epub 2019 Mar 12. Erratum in: Lancet Respir Med. 2019 Sep;7(9):e28.

PMID:
30876830
30.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.

Singh D, Agusti A, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Criner GJ, Frith P, Halpin DMG, Han M, López Varela MV, Martinez F, Montes de Oca M, Papi A, Pavord ID, Roche N, Sin DD, Stockley R, Vestbo J, Wedzicha JA, Vogelmeier C.

Eur Respir J. 2019 May 18;53(5). pii: 1900164. doi: 10.1183/13993003.00164-2019. Print 2019 May. Review.

PMID:
30846476
31.

Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation.

Singh D, Fabbri LM, Corradi M, Georges G, Guasconi A, Vezzoli S, Petruzzelli S, Papi A.

Eur Respir J. 2019 May 18;53(5). pii: 1900235. doi: 10.1183/13993003.00235-2019. Print 2019 May. No abstract available.

32.

Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study.

Papi A, Zheng J, Criner GJ, Fabbri LM, Calverley PMA.

Respir Med. 2019 Feb;147:37-43. doi: 10.1016/j.rmed.2018.12.014. Epub 2019 Jan 9.

PMID:
30704697
33.

Genomic stability, anti-inflammatory phenotype, and up-regulation of the RNAseH2 in cells from centenarians.

Storci G, De Carolis S, Papi A, Bacalini MG, Gensous N, Marasco E, Tesei A, Fabbri F, Arienti C, Zanoni M, Sarnelli A, Santi S, Olivieri F, Mensà E, Latini S, Ferracin M, Salvioli S, Garagnani P, Franceschi C, Bonafè M.

Cell Death Differ. 2019 Sep;26(9):1845-1858. doi: 10.1038/s41418-018-0255-8. Epub 2019 Jan 8.

PMID:
30622304
34.

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.

Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B.

Int J Chron Obstruct Pulmon Dis. 2018 Dec 12;13:3971-3981. doi: 10.2147/COPD.S185975. eCollection 2018. Review.

35.

Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee.

Criner GJ, Martinez FJ, Aaron S, Agusti A, Anzueto A, Bafadhel M, Barnes PJ, Bourbeau J, Chen R, Ewig J, Fabbri LM, Frith P, Halpin DMG, Han M, Montes de Oca M, Nishimura M, O'Donnell D, Papi A, Pavord I, Roche N, Rodriguez-Roisin R, Salvi S, Singh D, Sin DD, Stockley R, López Varela MV, Vestbo J, Vogelmeier CF, Washko G, Wedzicha JA, Celli BR.

Ann Am Thorac Soc. 2019 Jan;16(1):29-39. doi: 10.1513/AnnalsATS.201808-557PS. No abstract available.

PMID:
30427736
36.

Differential expression of RNA-binding proteins in bronchial epithelium of stable COPD patients.

Ricciardi L, Col JD, Casolari P, Memoli D, Conti V, Vatrella A, Vonakis BM, Papi A, Caramori G, Stellato C.

Int J Chron Obstruct Pulmon Dis. 2018 Oct 12;13:3173-3190. doi: 10.2147/COPD.S166284. eCollection 2018.

37.

Blood eosinophils for the management of COPD patients?

Fabbri LM, Beghé B, Papi A.

Lancet Respir Med. 2018 Nov;6(11):807-808. doi: 10.1016/S2213-2600(18)30417-X. Epub 2018 Oct 18. No abstract available.

PMID:
30343030
38.

Inhaled triple therapy in chronic obstructive pulmonary disease - Authors' reply.

Papi A, Singh D, Petruzzelli S, Guasconi A, Vestbo J.

Lancet. 2018 Sep 29;392(10153):1113-1114. doi: 10.1016/S0140-6736(18)31778-1. No abstract available.

PMID:
30303077
39.

Effects of Anti-IL-5 on Virus-induced Exacerbation in Asthma. Light and Shadow.

Contoli M, Papi A.

Am J Respir Crit Care Med. 2019 Feb 15;199(4):410-411. doi: 10.1164/rccm.201809-1684ED. No abstract available.

PMID:
30265568
40.

Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study.

Ferguson GT, Papi A, Anzueto A, Kerwin EM, Cappelletti C, Duncan EA, Nyberg J, Dorinsky P.

Eur Respir J. 2018 Sep 16;52(3). pii: 1801334. doi: 10.1183/13993003.01334-2018. Print 2018 Sep.

41.

Inhaled corticosteroid containing combinations and mortality in COPD.

Vestbo J, Fabbri L, Papi A, Petruzzelli S, Scuri M, Guasconi A, Vezzoli S, Singh D.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801230. doi: 10.1183/13993003.01230-2018. Print 2018 Dec. No abstract available.

PMID:
30209195
42.

Inhaled corticosteroids in COPD: friend or foe?

Agusti A, Fabbri LM, Singh D, Vestbo J, Celli B, Franssen FME, Rabe KF, Papi A.

Eur Respir J. 2018 Dec 13;52(6). pii: 1801219. doi: 10.1183/13993003.01219-2018. Print 2018 Dec. Review.

PMID:
30190269
43.

Epigallocatechin-3-gallate and 6-OH-11-O-Hydroxyphenanthrene Limit BE(2)-C Neuroblastoma Cell Growth and Neurosphere Formation In Vitro.

Farabegoli F, Govoni M, Spisni E, Papi A.

Nutrients. 2018 Aug 22;10(9). pii: E1141. doi: 10.3390/nu10091141.

44.

Diffuse pulmonary meningothelial like nodules simulating metastatic thymoma.

Tamburini N, Morandi L, Rinaldi R, Maniscalco P, Quarantotto F, Montinari E, Papi A, Anania G, Cavallesco G.

J Thorac Dis. 2018 Jun;10(6):E442-E446. doi: 10.21037/jtd.2018.05.178. No abstract available.

45.

Clinical and Pathologic Factors Predicting Future Asthma in Wheezing Children. A Longitudinal Study.

Bonato M, Bazzan E, Snijders D, Tinè M, Biondini D, Turato G, Balestro E, Papi A, Cosio MG, Barbato A, Baraldo S, Saetta M.

Am J Respir Cell Mol Biol. 2018 Oct;59(4):458-466. doi: 10.1165/rcmb.2018-0009OC.

PMID:
29812990
46.

Effects of bronchodilation on biomarkers of peripheral airway inflammation in COPD.

Santus P, Radovanovic D, Mascetti S, Pauletti A, Valenti V, Mantero M, Papi A, Contoli M.

Pharmacol Res. 2018 Jul;133:160-169. doi: 10.1016/j.phrs.2018.05.010. Epub 2018 May 23.

PMID:
29775687
47.

The anti-proliferative and anti-inflammatory response of COPD airway smooth muscle cells to hydrogen sulfide.

Perry MM, Tildy B, Papi A, Casolari P, Caramori G, Rempel KL, Halayko AJ, Adcock I, Chung KF.

Respir Res. 2018 May 9;19(1):85. doi: 10.1186/s12931-018-0788-x.

48.

Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma.

Busse WW, Maspero JF, Rabe KF, Papi A, Wenzel SE, Ford LB, Pavord ID, Zhang B, Staudinger H, Pirozzi G, Amin N, Akinlade B, Eckert L, Chao J, Graham NMH, Teper A.

Adv Ther. 2018 May;35(5):737-748. doi: 10.1007/s12325-018-0702-4. Epub 2018 May 3.

49.

Efficacy and safety profile of xanthines in COPD: a network meta-analysis.

Cazzola M, Calzetta L, Barnes PJ, Criner GJ, Martinez FJ, Papi A, Gabriella Matera M.

Eur Respir Rev. 2018 May 2;27(148). pii: 180010. doi: 10.1183/16000617.0010-2018. Print 2018 Jun 30. Review.

50.

Bronchial mucosal IFN-α/β and pattern recognition receptor expression in patients with experimental rhinovirus-induced asthma exacerbations.

Zhu J, Message SD, Mallia P, Kebadze T, Contoli M, Ward CK, Barnathan ES, Mascelli MA, Kon OM, Papi A, Stanciu LA, Edwards MR, Jeffery PK, Johnston SL.

J Allergy Clin Immunol. 2019 Jan;143(1):114-125.e4. doi: 10.1016/j.jaci.2018.04.003. Epub 2018 Apr 24.

Supplemental Content

Support Center